Publications by authors named "John Link"

Claim this Profile
D
Discovery of Lenacapavir: First-in-Class Twice-Yearly Capsid Inhibitor for HIV-1 Treatment and Pre-exposure Prophylaxis.
Eda Canales, Winston Tse, Scott D Schroeder, Chien-Hung Chou, Qi Liu, John O Link

J Med Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Edecesertib (GS-5718): A Potent, Selective Inhibitor of IRAK4.
Stephen E Ammann, Jeromy J Cottell, Nathan E Wright, Matthew R Warr, Chelsea A Snyder, John O Link

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance Pathway.
Jim Zheng, Bing Lu, Gavin Carr, Judy Mwangi, Kelly Wang, John O Link

J Pharmacol Exp Ther· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Hepatitis B Virus Surface Antigen Suppressor GS-8873.
Darryl Kato, Regina Wai-Yan Choy, Eda Canales, Ryan A Dick, April D Lake, John O Link

ACS Med Chem Lett· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie Ann Holmes, John S Link

Clin Breast Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical targeting of HIV capsid protein with a long-acting small molecule.
John O Link, Martin S Rhee, Winston C Tse, Jim Zheng, John R Somoza

Nature· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model.
Stephen R Yant, Andrew Mulato, Derek Hansen, Winston C Tse, Anita Niedziela-Majka, John O Link

Nat Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi.
James G Taylor, Sheila Zipfel, Kyla Ramey, Randy Vivian, Adam Schrier, John O Link

Bioorg Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi and Epclusa.
John O Link, James G Taylor, Alejandra Trejo-Martin, Darryl Kato, Ashley A Katana

Bioorg Med Chem Lett· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Miguel Martin, Frankie A Holmes, Bent Ejlertsen, Suzette Delaloge, Beverly Moy, John S Link

Lancet Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects.
Erik Mogalian, Polina German, Brian P Kearney, Cheng Yong Yang, Diana Brainard, John Link

Antimicrob Agents Chemother· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein.
Eric J Lawitz, Hadas Dvory-Sobol, Brian P Doehle, Angela S Worth, John McNally, John O Link

Antimicrob Agents Chemother· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to Discovery of Ledipasvir (GS-5885): A Potent, Once-Daily Oral NS5A Inhibitor for the Treatment of Hepatitis C Virus Infection.
John O Link, James G Taylor, Lianhong Xu, Michael Mitchell, Hongyan Guo

J Med Chem· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction for Hyman et al., Evaluation of a Fully Automated Research Prototype for the Immediate Identification of Microorganisms from Positive Blood Cultures under Clinical Conditions.
Jay M Hyman, John D Walsh, Christopher Ronsick, Mark Wilson, Kevin C Hazen, John Link

mBio· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Fully Automated Research Prototype for the Immediate Identification of Microorganisms from Positive Blood Cultures under Clinical Conditions.
Jay M Hyman, John D Walsh, Christopher Ronsick, Mark Wilson, Kevin C Hazen, John Link

mBio· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
Guofeng Cheng, Yang Tian, Brian Doehle, Betty Peng, Amoreena Corsa, John O Link

Antimicrob Agents Chemother· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.
Hyock Joo Kwon, Weimei Xing, Katie Chan, Anita Niedziela-Majka, Katherine M Brendza, John O Link

PLoS One· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection.
John O Link, James G Taylor, Lianhong Xu, Michael Mitchell, Hongyan Guo

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rapid intrinsic fluorescence method for direct identification of pathogens in blood cultures.
John D Walsh, Jay M Hyman, Larisa Borzhemskaya, Ann Bowen, Caroline McKellar, John Link

mBio· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Project connect online: randomized trial of an internet-based program to chronicle the cancer experience and facilitate communication.
Annette L Stanton, Elizabeth H Thompson, Catherine M Crespi, John S Link, James R Waisman

J Clin Oncol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.
Christy M Hebner, Bin Han, Katherine M Brendza, Michelle Nash, Maisoun Sulfab, John Link

PLoS One· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.
Eric J Lawitz, Daniel Gruener, John M Hill, Thomas Marbury, Lisa Moorehead, John O Link

J Hepatol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of GS-9451: an acid inhibitor of the hepatitis C virus NS3/4A protease.
X Christopher Sheng, Todd Appleby, Thomas Butler, Ruby Cai, Xiaowu Chen, John Link

Bioorg Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons learned from 14 years of outcomes: the need for collaboration, utilization, and projection.
Jacqueline Remondet Wall, Steven M Koch, John W Link, Cathleen Graham

Child Welfare· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Mary L Disis, Danelle R Wallace, Theodore A Gooley, Yushe Dang, Meredith Slota, John Link

J Clin Oncol· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis